Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO James W. Green Purchases 10,000 Shares

Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO James W. Green purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average price of $2.61 per share, for a total transaction of $26,100.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of NASDAQ:HBIO traded up $0.21 during mid-day trading on Thursday, reaching $2.66. 4,605 shares of the company traded hands, compared to its average volume of 93,542. The company’s 50 day moving average price is $2.86 and its 200-day moving average price is $2.54. The firm has a market cap of $98.16 million, a PE ratio of 17.47 and a beta of 1.49. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.52 and a quick ratio of 1.30. Harvard Bioscience, Inc. has a 52 week low of $1.51 and a 52 week high of $4.66.

A number of research analysts recently issued reports on the company. ValuEngine downgraded Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Tuesday, October 22nd. Benchmark reiterated a “buy” rating on shares of Harvard Bioscience in a research note on Friday, July 19th. Finally, Zacks Investment Research upgraded Harvard Bioscience from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research note on Tuesday.

Several large investors have recently made changes to their positions in HBIO. Engine Capital Management LP bought a new position in shares of Harvard Bioscience during the 2nd quarter valued at approximately $3,736,000. Dalton Greiner Hartman Maher & Co. grew its stake in shares of Harvard Bioscience by 1,207.4% during the 2nd quarter. Dalton Greiner Hartman Maher & Co. now owns 1,155,376 shares of the medical instruments supplier’s stock valued at $2,311,000 after acquiring an additional 1,067,007 shares during the period. River & Mercantile Asset Management LLP bought a new position in shares of Harvard Bioscience during the 2nd quarter valued at approximately $1,114,000. Assenagon Asset Management S.A. grew its stake in shares of Harvard Bioscience by 3,295.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 440,346 shares of the medical instruments supplier’s stock valued at $1,354,000 after acquiring an additional 427,379 shares during the period. Finally, Wedge Capital Management L L P NC bought a new position in shares of Harvard Bioscience during the 3rd quarter valued at approximately $1,071,000. Institutional investors own 61.74% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.

Further Reading: Conference Calls and Individual Investors

Insider Buying and Selling by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.